Desmond A O'Farrell, M.Sc.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brachytherapy | 26 | 2023 | 1246 | 1.660 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 13 | 2023 | 1622 | 0.620 |
Why?
|
Radiotherapy Dosage | 22 | 2023 | 2876 | 0.450 |
Why?
|
Uterine Cervical Neoplasms | 5 | 2021 | 2011 | 0.300 |
Why?
|
Carcinoma, Merkel Cell | 3 | 2013 | 299 | 0.230 |
Why?
|
Genital Neoplasms, Female | 2 | 2023 | 516 | 0.230 |
Why?
|
Rectum | 5 | 2017 | 903 | 0.210 |
Why?
|
Penile Neoplasms | 1 | 2020 | 159 | 0.160 |
Why?
|
Radiation Injuries | 3 | 2013 | 1178 | 0.150 |
Why?
|
Iodine Radioisotopes | 3 | 2009 | 1030 | 0.140 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2016 | 68 | 0.140 |
Why?
|
Colon, Sigmoid | 3 | 2017 | 118 | 0.140 |
Why?
|
Organs at Risk | 2 | 2017 | 346 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2016 | 9185 | 0.130 |
Why?
|
Software Validation | 1 | 2014 | 59 | 0.120 |
Why?
|
Catheters | 3 | 2023 | 422 | 0.120 |
Why?
|
Radiotherapy, Computer-Assisted | 2 | 2010 | 94 | 0.110 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2012 | 59 | 0.110 |
Why?
|
Radiometry | 4 | 2014 | 800 | 0.100 |
Why?
|
Catheters, Indwelling | 1 | 2014 | 425 | 0.100 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2012 | 221 | 0.100 |
Why?
|
Skin Diseases | 1 | 2020 | 1065 | 0.100 |
Why?
|
Chordoma | 3 | 1999 | 359 | 0.100 |
Why?
|
Prostatic Neoplasms | 4 | 2014 | 11039 | 0.090 |
Why?
|
Skull Base Neoplasms | 3 | 1999 | 284 | 0.090 |
Why?
|
Endometrial Neoplasms | 2 | 2012 | 1351 | 0.090 |
Why?
|
Urinary Bladder | 3 | 2017 | 1171 | 0.080 |
Why?
|
Carcinoid Tumor | 2 | 2009 | 235 | 0.080 |
Why?
|
Radiation Protection | 1 | 2012 | 419 | 0.080 |
Why?
|
Skin Neoplasms | 3 | 2013 | 5662 | 0.080 |
Why?
|
Imaging, Three-Dimensional | 2 | 2013 | 4029 | 0.080 |
Why?
|
Salvage Therapy | 1 | 2014 | 1269 | 0.080 |
Why?
|
Thoracic Neoplasms | 1 | 2009 | 268 | 0.070 |
Why?
|
Polyethylene Glycols | 1 | 2012 | 1181 | 0.070 |
Why?
|
Stereotaxic Techniques | 1 | 2008 | 535 | 0.070 |
Why?
|
Vaginal Neoplasms | 1 | 2006 | 106 | 0.070 |
Why?
|
Neoplasm Metastasis | 2 | 2013 | 4839 | 0.060 |
Why?
|
Radiotherapy | 2 | 2008 | 1525 | 0.060 |
Why?
|
Sarcoma | 2 | 2013 | 1895 | 0.060 |
Why?
|
Consensus | 1 | 2013 | 2935 | 0.060 |
Why?
|
Mediastinal Neoplasms | 1 | 2006 | 421 | 0.060 |
Why?
|
Uterine Neoplasms | 1 | 2012 | 1513 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 5 | 2023 | 35342 | 0.060 |
Why?
|
Treatment Outcome | 12 | 2020 | 62966 | 0.050 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2013 | 876 | 0.050 |
Why?
|
Ultrasonography | 1 | 2014 | 5978 | 0.050 |
Why?
|
Aged, 80 and over | 11 | 2020 | 57683 | 0.050 |
Why?
|
Societies, Medical | 1 | 2013 | 3740 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2016 | 4029 | 0.050 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2013 | 1769 | 0.040 |
Why?
|
Aged | 17 | 2020 | 162944 | 0.040 |
Why?
|
Cicatrix | 1 | 2005 | 761 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2016 | 6347 | 0.040 |
Why?
|
Breast Neoplasms | 3 | 2013 | 20774 | 0.040 |
Why?
|
Humans | 31 | 2023 | 742088 | 0.040 |
Why?
|
Photons | 2 | 1999 | 587 | 0.040 |
Why?
|
Automation | 1 | 2020 | 584 | 0.040 |
Why?
|
Radiation Dosage | 2 | 2017 | 1927 | 0.040 |
Why?
|
Middle Aged | 15 | 2020 | 213127 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 6 | 2020 | 20086 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2013 | 7276 | 0.030 |
Why?
|
Chondrosarcoma | 1 | 1998 | 309 | 0.030 |
Why?
|
Vagina | 2 | 2012 | 825 | 0.030 |
Why?
|
Female | 18 | 2023 | 379592 | 0.030 |
Why?
|
SEER Program | 1 | 2020 | 1507 | 0.030 |
Why?
|
Mammaplasty | 1 | 2005 | 1195 | 0.030 |
Why?
|
Mammography | 1 | 2005 | 2474 | 0.030 |
Why?
|
Protons | 1 | 1998 | 1126 | 0.030 |
Why?
|
Retrospective Studies | 7 | 2017 | 77098 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 2008 | 4249 | 0.030 |
Why?
|
Brain Stem | 1 | 1997 | 844 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2014 | 39004 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2014 | 5062 | 0.020 |
Why?
|
Tumor Burden | 1 | 2016 | 1905 | 0.020 |
Why?
|
Temporal Lobe | 1 | 1998 | 1669 | 0.020 |
Why?
|
Adult | 11 | 2017 | 213712 | 0.020 |
Why?
|
Watchful Waiting | 1 | 2014 | 491 | 0.020 |
Why?
|
Male | 13 | 2020 | 349538 | 0.020 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6891 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2013 | 6365 | 0.020 |
Why?
|
Survival Rate | 2 | 2013 | 12773 | 0.020 |
Why?
|
Mastectomy | 2 | 2008 | 1789 | 0.020 |
Why?
|
Neoplasm Staging | 2 | 2013 | 11001 | 0.020 |
Why?
|
Mastectomy, Segmental | 1 | 2013 | 955 | 0.020 |
Why?
|
Mediastinum | 1 | 2009 | 267 | 0.020 |
Why?
|
Time Factors | 3 | 2016 | 40054 | 0.020 |
Why?
|
Particle Accelerators | 1 | 2008 | 173 | 0.020 |
Why?
|
Technology, Radiologic | 1 | 2007 | 163 | 0.020 |
Why?
|
Hydrogels | 1 | 2012 | 723 | 0.020 |
Why?
|
Prospective Studies | 5 | 2013 | 53187 | 0.020 |
Why?
|
Prostate | 1 | 2014 | 1764 | 0.020 |
Why?
|
Urethra | 1 | 2008 | 408 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6534 | 0.020 |
Why?
|
Ultrasonography, Interventional | 1 | 2014 | 1483 | 0.020 |
Why?
|
Remission Induction | 1 | 2011 | 2384 | 0.020 |
Why?
|
Leg | 1 | 2010 | 1110 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2013 | 3612 | 0.020 |
Why?
|
Skin Transplantation | 1 | 2010 | 1074 | 0.020 |
Why?
|
Leiomyosarcoma | 1 | 2009 | 477 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2009 | 974 | 0.020 |
Why?
|
Combined Modality Therapy | 2 | 2011 | 8621 | 0.010 |
Why?
|
Pelvis | 1 | 2008 | 730 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2014 | 19862 | 0.010 |
Why?
|
Linear Models | 1 | 2013 | 5948 | 0.010 |
Why?
|
Therapy, Computer-Assisted | 1 | 2005 | 277 | 0.010 |
Why?
|
Equipment Design | 1 | 2010 | 3582 | 0.010 |
Why?
|
Survival Analysis | 1 | 2014 | 10248 | 0.010 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2008 | 1101 | 0.010 |
Why?
|
Phantoms, Imaging | 1 | 2008 | 2466 | 0.010 |
Why?
|
Massachusetts | 1 | 2013 | 8662 | 0.010 |
Why?
|
Breast | 1 | 2008 | 1958 | 0.010 |
Why?
|
Adolescent | 4 | 2016 | 85649 | 0.010 |
Why?
|
Neoplasms | 1 | 2008 | 21596 | 0.010 |
Why?
|
Palliative Care | 1 | 2013 | 3478 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2006 | 3471 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2008 | 3465 | 0.010 |
Why?
|
Young Adult | 2 | 2016 | 56350 | 0.010 |
Why?
|
Prevalence | 1 | 2013 | 15194 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 11472 | 0.010 |
Why?
|
Heart | 1 | 2008 | 4462 | 0.010 |
Why?
|
Pilot Projects | 1 | 2006 | 8297 | 0.010 |
Why?
|
Quality of Life | 1 | 2014 | 12730 | 0.010 |
Why?
|
Prognosis | 1 | 2013 | 29010 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2008 | 7901 | 0.010 |
Why?
|
Risk Assessment | 1 | 2013 | 23320 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 5171 | 0.010 |
Why?
|
Cohort Studies | 1 | 2013 | 40450 | 0.010 |
Why?
|
Lung | 1 | 2008 | 9826 | 0.010 |
Why?
|
Algorithms | 1 | 2007 | 13853 | 0.000 |
Why?
|
Sex Factors | 1 | 1999 | 10392 | 0.000 |
Why?
|
United States | 1 | 2013 | 69693 | 0.000 |
Why?
|
Proportional Hazards Models | 1 | 1999 | 12344 | 0.000 |
Why?
|
Lung Neoplasms | 1 | 2009 | 13019 | 0.000 |
Why?
|
Multivariate Analysis | 1 | 1997 | 12242 | 0.000 |
Why?
|
Child | 2 | 1998 | 77478 | 0.000 |
Why?
|